The U.S. Food and Drug Administration on Wednesday approved the first pill form of fecal microbiota — similar to what’s known as fecal transplant therapy — to treat the bacterial infection Clostridioides difficile, one of the most common and deadly infections found in health care settings.
The drug, Vowst, is approved to prevent recurrence of C. difficile in people who have already had standard antibacterial treatment for recurrent infection. It contains live gut bacteria from stool samples donated by healthy people.
